Clinical Trial Update: Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 multi-center trial of ESK981 in combination with nivolumab for metastatic renal cell carcinoma was terminated, and results were posted on 2024-05-20.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ESK981
• nivolumab (nivolumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Renal Cell Carcinoma, Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2024-05-20